Treats Attention Deficit Hyperactivity Disorder (ADHD). ANDA 203583, held by SpecGx. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 203583 (Methylphenidate Hydrochloride), held by SpecGx, was first approved by FDA on Sep 29, 2015, with 5 approved supplements and 0 published complete response letters.
Methylphenidate HCl extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age. Limitations of Use The use of methylphenidate HCl extended-release capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 2015 | Original application | Approved |
| Methylphenidate Hydrochloride10MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride20MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride30MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride40MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride50MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride60MG · capsule, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Oct 7, 2024 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 7, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 7, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 7, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 28, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 29, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters